NASDAQ
7.35USD
0.00 (0.00%)
We have scored 16 news catalysts on Atai Beckley Inc. (ATAI) over the past 12 months. The biggest single-day move next to one of them came Apr 24, 2026, when ATAI closed −2.9%: “Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About”. Coverage across the window leans positive (average ticker sentiment +0.68). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.7B
P/E
—
EPS
—
Beta
1.55
52W range
3.265-7.45
Day range
7.35–7.35
Open
7.35
Prev close
7.35
Volume
0
Avg volume
11.5M
Dividend
6.75
IPO
2021-06-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Atai Beckley Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ATAI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
